CAS 948564-73-6

Fresolimumab

Description:

Fresolimumab is a monoclonal antibody that targets the cytokine transforming growth factor-beta (TGF-β), which plays a crucial role in various cellular processes, including immune regulation and tissue repair. It is primarily investigated for its potential therapeutic applications in autoimmune diseases, fibrosis, and certain cancers. As a human IgG1κ antibody, Fresolimumab is designed to neutralize TGF-β activity, thereby modulating the immune response and inhibiting fibrotic processes. The substance is characterized by its high specificity for TGF-β, which allows it to effectively block its signaling pathways. Fresolimumab is typically administered via injection and has undergone various clinical trials to assess its efficacy and safety profile. Its development reflects a growing interest in targeting cytokines for therapeutic intervention in complex diseases. As with many biologics, the stability, storage conditions, and formulation are critical for maintaining its activity and effectiveness.

Formula: Unspecified

Synonyms:

• GC 1008
• Fresolimumab
• Immunoglobulin G4, anti-(transforming growth factor β) (human monoclonal GC-1008 heavy chain), disulfide with human monoclonal GC-1008 light chain, dimer

Fresolimumab

CAS: 948564-73-6

Fresolimumab (GC1008) is a human monoclonal antibody targeting active TGFβ1, TGFβ2, TGFβ3, studied for cancer and focal segmental glomerulosclerosis.

Purity: > 95% - > 95%

Color and Shape: Liquid

Molecular weight: 144.4 kDa

Ref: TM-T76681

Fresolimumab

CAS: 948564-73-6

Anti-Human TGFB Monoclonal Antibody

Ref: 3D-CLA1141